Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Canada / NCT05805319
Recruiting Not applicable

Dietary Intervention for NSCLC Patients Treated With ICI

NCT05805319 · tracked via the Priya Life Science Canada tracker
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Phase
Not applicable
Started
2023-04-27
Last updated
2026-10-22

Condition(s) studied

Non Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

increasing total fiber intake

increasing total fiber intake: Patients in the intervention arm will complete a dietary survey and be counselled on increasing their total fiber intake.

Study summary

This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Signed, informed consent * Age 18 years or older * Confirmed histological diagnosis of non-small cell lung cancer (NSCLC); Treatment with standard-of-care ICI * Ability to eat solid foods Exclusion Criteria: * Severe dietary allergies (e.g. shellfish, nuts, seafood) * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Primary outcome measure(s)

  • Proportion of patients in the intervention arm (nutritionist intervention) with total daily fiber intake of >=25g/day compared to the control arm (no nutritionist intervention). — 12 weeks
    Proportion of patients in the intervention arm (nutritionist intervention) with total daily fiber intake of \>=25g/day compared to the control arm (no nutritionist intervention).

Trial sites (1)

FacilityCityRegionStatus
Centre hospitalier de l'Université de Montréal (CHUM) Montreal Quebec Recruiting

More Centre hospitalier de l'Université de Montréal (CHUM) trials in Canada

Routine vs On-demand ECMO for Lung Transplantation Recruiting
Methionine Intake Microbiota Recruiting
Comprehensive Aneurysm Management Trial Recruiting
Restrictive Fluid Management In Liver Transplantation (REFIL) - Pilot Active, not recruiting
Glycemic Control and Osteohealth in Adults Living With Type 1 Diabetes Recruiting

Other trials for the same condition

Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC Recruiting
Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease Active, not recruiting
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors Active, not recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) Recruiting
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05805319 on ClinicalTrials.gov ↗ ← All trials in Canada